RxDoctor Payments Data

Maureen Ziboh, MD

Family Medicine · Edwardsburg, MINPI 1275560583

Payments from drug & device makers

$378in general payments, 2019–2025

Across 15 payments — averaging $25.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$125
  • AbbVie$61
  • Boehringer Ingelheim$30
  • Genentech USA, Inc.$28
  • GSK$26
  • Novo Nordisk$24
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$34892%
  • Education$308%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$378 in reported general payments places this provider in the 55th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$16,397
Medicare patients
90
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$120,603
MounjaroTirzepatide66$73,030
LinzessLinaclotide36$41,153
EliquisApixaban39$26,908
VraylarCariprazine Hcl14$20,096
XareltoRivaroxaban29$18,438
NamzaricMemantine Hcl/Donepezil Hcl20$16,430
JardianceEmpagliflozin15$15,526
Lagevrio (Eua)Molnupiravir14$14,116
Breo ElliptaFluticasone/Vilanterol15$12,807
JanuviaSitagliptin Phosphate12$12,254
RybelsusSemaglutide11$12,098
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$9,611
ErtapenemErtapenem Sodium39$6,237
Albuterol Sulfate HfaAlbuterol Sulfate99$3,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$24$132,702106 claims
AbbVieLinzess, Vraylar, Namzaric$61$77,67970 claims
Lilly USA, LLCMounjaro, Olanzapine$125$73,59394 claims
GSKBreo Ellipta, Trelegy Ellipta$26$22,41832 claims
Boehringer IngelheimJardiance$30$15,52615 claims
AstraZenecaSymbicort$15$2,85512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Edwardsburg

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →